



3475 Edison Way, Ste. R, Menlo Park, CA 94025 tel (650) 995-7508

## **NewGen Therapeutics to Present Data for NT113, a Potent Irreversible Pan-erbB Inhibitor, at the American Association of Cancer Research Meeting**

**MENLO PARK, CA (April 3, 2013)** -- NewGen Therapeutics, Inc. today announced that it will present an abstract entitled "*NT113, A Potent and Selective Pan-erbB inhibitor, is Efficacious in Vivo and Has High Brain Penetration*" at the American Association of Cancer Research Meeting (AACR), being held April 6-10, 2013 in Washington, D.C.

The NT113 presentation (abstract #2089) will be on Monday, April 8<sup>th</sup> from 1:00-5:00 pm in the Experimental and Molecular Therapeutics Section.

### **About NewGen**

NewGen Therapeutics is a privately held pharmaceutical company developing patient-targeted cancer drugs that are designed to overcome limitations of currently available therapies. The company's pipeline includes multiple programs with novel small molecule drug leads against clinically important targets, each addressed to significant medical needs. NT113, a potent irreversible pan-erbB inhibitor, is the company's most advanced program and has demonstrated anti-cancer activity in several cancer xenograft studies, including glioblastoma. NT113 will enter Phase 1 clinical trials in early 2014.

NewGen's strategy is to identify and in-license promising programs, add value through further development and then partner with pharmaceutical companies for clinical development and commercialization. For more information, please visit our website at <http://www.newgenther.com>.

###

### **For Further Information Contact:**

Harry Pedersen  
NewGen Therapeutics  
+1.650.995.7508 ext. 101  
[ir@newgenther.com](mailto:ir@newgenther.com)

### **For Media Inquiries:**

Joan Kureczka  
Kureczka/Martin Associates  
+1.415.821.2413  
[Joan@kureczka-martin.com](mailto:Joan@kureczka-martin.com)